Norwich Pharmaceuticals

Dan Casey has been appointed vice president business development, and Dale A. Dyer was named director of business development at Norwich Pharmaceuticals.

Mr. Casey has more than 20 years of experience in the pharmaceutical industry. Most recently, he served as general manager and director of sales for Covidien Inc., where he managed the outsourcing and contract manufacturing business. Prior to that, he held general manager and site director positions at Mallinckrodt, and served as president of D.M. Graham Laboratories.

Chris Calhoun, president of Norwich Pharmaceuticals, commented, “Dan Casey is a visionary with a global perspective and a proven ability to plan, develop and implement programs vital to meet present and future industry demands. In tandem with Dale Dyer, we expect to have a significant influence on the success of our clients well into the future. Dale has a demonstrated ability to generate and execute an effective business development strategy from the ground up. She will be vital in helping us make the most of our recent specialized equipment investments”

Mr. Casey commented, “Norwich has made an unprecedented commitment to our industry’s need for flexibility. This is where I belong at this point in the evolution of our industry and in my career.”

Ms. Dyer has more than 25 years of experience in marketing and sales of contract manufacturing services and brand and generic pharmaceutical products. Most recently, she held senior positions at Covidien, Tyco Healthcare and Mallinckrodt Inc., including serving as marketing and sales manager for Covidien since 1996. Earlier in her career she received several national sales awards and achieved top honors while at Glaxo/SmithKlineBeecham and Stuart Pharmaceuticals.

“In the past, Norwich limited its scope of services to manufacturing, packaging, and quality control testing support,” said Ms. Dyer. “We will now assist customers throughout the life cycle of a product, as well as help plan and launch new initiatives, from simple line extensions to explorations into new product categories.”